Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07286331 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)

Name: A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01) — clinical trial record (NCT07286331)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 3

SponsorGlaxoSmithKline

Started2026-06-04

View on ClinicalTrials.gov ↗

This study specifically aims to evaluate how well mocertatug rezetecan (Mo-Rez) works in treating Endometrial Cancer (EC) compared to standard of care. The study also assesses whether Mo-Rez is safe and tolerated well by participants in comparison to standard of care and will help provide a better understanding of the main side effects of the drugs.

Amendment history 4 changes detected by DataLookout

2026-09-01

Trial sites expanded: 18 → 28 locations

2026-07-16

Trial sites expanded: 14 → 18 locations

2026-07-03

Recruitment opened

2026-07-03

Trial sites expanded: 0 → 14 locations

Trial Details

NCT Number	NCT07286331
Lead Sponsor	GlaxoSmithKline Collaborators: ENGOT, GOG, APGOT
Conditions	Neoplasms, Endometrial
Enrollment	600 participants
Start Date	2026-06-04
Primary Completion	2028-02-29 (estimated)
Study Completion	2029-05-30 (estimated)
Updated on ClinicalTrials.gov	2026-08-31